US drug giant is one of four vaccine developers running late-stage trials in SA.

If approved, Aspen Pharmacare will manufacture 300m doses a year in South Africa.

Nick Kunze of Sanlam Private Wealth looks at the JSE overall, Sasol and Aspen.

Sanlam's Nick Kunze on a storming start to the JSE in 2021, what’s driving it? Mike Gresty, Anchor Capital CIO, on their top local stock picks for the year.

In best start to year since 1999.

Vaccines for exports unless government, J&J sign deal.

SA may have to wait months before it sees its first Covid vaccines.

SA yet to announce firm strategy to immunise its population.

Wants to be one of the frontline countries to secure the vaccines.

SA looks set to achieve its ambitious investment target of R1.2trn by 2023 despite the impact of the pandemic.

More than 50 big companies are already backing B4SA's #PayIn30 initiative.

In virus response.

It will take about six weeks to enrol 12 000 volunteers.

Gary Booysen of Rand Swiss on the Aspen vaccine announcement, AngloGold doubling its dividend and the US election. Glen Gerber, Santova CEO, talks their strong results and global supply chains returning to normal. Taurus Capital founder Simon Kuper on launching an R80m litigation fund.

Gus Attridge – CFO, Aspen Pharmacare